Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458507077896v1
13/8/981    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De las Heras, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De las Heras, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on September 1, 2007
Multiple Sclerosis, Vol. 13, No. 8, 981-984 (2007)
DOI: 10.1177/1352458507077896
© 2007 SAGE Publications

Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population

V. De las Heras

Servicio de Neurología, Hospital Clínico San Carlos, 28040 Madrid, Spain, v_delasheras{at}yahoo.es

C. De Andrés

Servicio de Neurología, Hospital Gregorio Marañón, 28007 Madrid, Spain

N. Téllez

Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall D'hebron, 08035 Barcelona, Spain

M. Tintoré

Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall D'hebron, 08035 Barcelona, Spain

on behalf of the EMPATIE Study Group, Spain

Objectives To study the management of pregnancy in multiple sclerosis (MS) patients on immunomodulatory therapy (IMT) in routine clinical practice and to analyze pregnancy outcomes and the clinical course of MS around pregnancy.

Methods Retrospective, multicentric study in Spain in MS patients receiving IMT before conception and followed for at least three months post-partum.

Results A total of 1286 medical records were reviewed. Eighty-eight pregnancies were identified in 74 (6%) women, 66% of which were unexposed and 34% exposed pregnancies. In most cases, IMT was discontinued before conception and resumed shortly after delivery. Accidental exposure to IMT did not lead to higher rates of abortions (P = 0.76) or malformations. The relapse rate was decreased during pregnancy (0.31 versus 0.61 in the pre-pregnancy year) and increased after delivery (0.87 on month 3), returning to pre-conception values on month 12. The median EDSS score was not increased during the study.

Conclusions Discontinuation of IMT before conception, and resumption shortly after delivery was the most frequent clinical practice procedure. Accidental exposure to IMT did not affect pregnancy outcomes or increased malformation rates. Pregnancy was associated with a reduced relapse rate. No factor was found to predict the risk of relapses during or after pregnancy. Multiple Sclerosis 2007; 13: 981—984. http://msj.sagepub.com

Key Words: accidental exposure • disability • immunomodulatory treatment • pregnancy • relapse rate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?